Market
Will Gilead launch generic Lenacapavir in 120 countries by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Gilead press releases and international health news reports
Story
Twice-Yearly HIV Prevention Shot: 96% Effective in Men, 100% in Women
Dec 1, 2024, 12:50 PM
A new study has shown that Lenacapavir, a twice-yearly injectable pre-exposure prophylaxis (PrEP), is highly effective in preventing HIV infections, with a 96% reduction in risk for men and 100% effectiveness in women. Despite its potential, concerns have been raised about equitable access, cost-effectiveness, and adherence challenges. Gilead, the developer of the drug, has announced plans to allow the sale of generic versions of Lenacapavir in 120 countries with high HIV rates to address affordability issues. The World Health Organization (WHO) is currently reviewing the drug for initial approval, which could significantly impact HIV prevention strategies globally.
View original story
Similar markets
No • 50%
Yes • 50%
Yes • 50%
No • 50%
More than 90 countries • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
Less than 50 • 25%
More than 120 • 25%
81 to 120 • 25%
50 to 80 • 25%
Yes • 50%
No • 50%
More than 120 countries • 25%
50 to 80 countries • 25%
Less than 50 countries • 25%
81 to 120 countries • 25%
Pfizer • 25%
Other • 25%
Roche • 25%
Johnson & Johnson • 25%
5-9 countries • 25%
1-4 countries • 25%
15 or more countries • 25%
10-14 countries • 25%